SLC34A2 and cancer: In the future, we plan to generate new monoclonal antibodies and test their ability to bind wild-type and the p.T330M mutant form of NaPi2b, as well as expand our studies by focusing on identifying mutations in the NaPi2b transporter in cancer patients beyond the MX35 epitope.